

Supplementary Table S1. Patient characteristics between periods.

	PsA (n=420)	RA (n=583)	SpA (n=384)	Overall (n=1387)
Age, mean (SD)	48.5 (13.2)	52.9 (14.4)	43.0 (13.0)	48.8 (14.2)
Sex: female	247 (58.8%)	439 (75.3%)	132 (34.4%)	818 (59.0%)
Years from diagnosis, mean (SD)	6.95 (7.76)	8.17 (9.33)	6.98 (9.58)	7.48 (8.98)
HAQ at baseline, mean (SD)	1.13 (0.657)	1.18 (0.667)	0.867 (0.567)	1.07 (0.650)
DAS28-CRP at baseline mean (SD)	4.32 (1.06)	4.79 (1.13)	3.07 (0.900)	4.18 (1.27)
DDD of GC for 2 years following TNFi, mean (SD)	50.5 (115)	138 (192)	32.9 (83.0)	82.4 (154)
DDD of GC for 2 years before TNFi, mean (SD)	75.5 (138)	200 (227)	48.9 (125)	120 (191)
Serious infections for 2 years before TNFi				
Events per 1000 PY (95% CI)	21.4 (12.7–33.9)	29.2 (20.2–40.8)	7.8 (2.9–17)	20.9 (15.9–27)
Serious infections for 2 years following TNFi				
Events per 1000 PY (95% CI)	28.6 (18.2–43)	37.5 (26.9–50.9)	23.3 (13.6–37.2)	30.8 (24.5–38.3)
Antimicrobial prescriptions for 2 years before TNFi				
Events per 1000 PY (95% CI)	1305 (1229–1384)	1413 (1346–1483)	1095 (1022–1172)	1292 (1250–1335)
Antimicrobial prescriptions for 2 years after TNFi				
Events per 1000 PY (95% CI)	1650 (1563–1742)	1804 (1725–1886)	1449 (1363–1539)	1658 (1609–1708)

DAS28-CRP: Disease Activity Score 28-joint count and C-reactive protein; DDD: defined daily doses; GC: glucocorticoids; HAQ: Health Assessment Questionnaire; PsA: psoriatic arthritis; RA: rheumatoid arthritis; SpA: spondyloarthritis; VAS: visual analogue score.